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Induction of TGF-b1 by the matricellular protein SPARC in these structurally unrelated glycoproteins have common
a rat model of glomerulonephritis. activities that manifest themselves through distinct do-
Background. SPARC has been implicated as a counteradhe- mains. They can bind to and affect the properties of thesive and antiproliferative protein associated with deposits of
ECM; however, they do not appear to function primarilyextracellular matrix in renal disease.
as structural components. For example, SPARC is recog-Method. We have examined the effect of recombinant
SPARC containing a C-terminal His tag (rSPARC) in an acute nized for its ability to bind to collagen via a Ca21-depen-
model of mesangial cell injury that is induced in the rat by dent mechanism [3] and for its absence extracellularly
an antibody against the Thy1 antigen on the mesangial cell in mov 13 mice that lack expression of type I collagenmembrane. The recombinant protein was administered 24
[4]. Matricellular proteins can also bind to and regulatehours after the induction of nephritis and was infused through
the activity of growth factors and cytokines. Thrombo-day 4.
Results. rSPARC was localized to the renal glomeruli of rats spondin-1 was recently shown to be responsible for a
treated with anti-Thy1 antibody. Type I collagen and fibronec- significant proportion of the activation of transforming
tin, as well as transforming growth factor-b1 (TGF-b1), were growth factor (TGF)-b1 in vivo [5].increased at day 5 in rats treated with rSPARC (N 5 4, P ,
Studies in vitro have elucidated a variety of functions0.05 vs. delivery buffer), but only minimal effects were seen
for SPARC that include inhibition of proliferation of aon mesangial cell and endothelial cell proliferation. In primary
cultures of rat mesangial cells, infusion of rSPARC was associ- variety of cell types [3, 6], modulation of endothelial cell
ated with increases in TGF-b1 mRNA and in total, secreted permeability [7], and disruption of ECM interactions by
TGF-b1 protein. countering the adhesive actions of vitronectin [8] andConclusions. rSPARC stimulates expression of TGF-b1 both
other ECM proteins [3]. Expression of SPARC is alsoin vitro and in vivo. Given the closely regulated expression of
coincident with the deposition of type I collagen [9].SPARC, TGF-b1, and type I collagen in several animal models
of glomerulonephritis, we propose that SPARC could be one A role for SPARC in experimental renal disease has
of the major mediators of the induction of TGF-b1 in renal been indicated by several studies, for example, as an
disease. endogenous inhibitor of cell proliferation. SPARC is
synthesized by mesangial cells in culture, inhibits mesan-
gial cell proliferation in vitro, and is expressed transientlyMatricellular proteins comprise a group of secreted
by mesangial cells in experimental mesangial prolifera-macromolecules that influence cell–extracellular matrix
tive nephritis in association with the subsequent decline(ECM) interactions, in some instances through receptor-
in mesangial cell proliferation [10]. SPARC is also syn-mediated intracellular signaling events [1, 2]. A hallmark
thesized by podocytes. These visceral epithelial cells ofcharacteristic of SPARC (secreted protein acidic and rich
the glomerulus rarely proliferate [11], but undergo sig-in cysteine), tenascin C, and thrombospondin-1 is that
nificant changes in cell shape [12] and in the production
of SPARC in various experimental models of disease
[13], the consequences of which might be important inKey words: anti-thymocyte serum, Thy 1, extracellular matrix, renal
disease, collagen type 1, cell proliferation. progressive glomerular scarring [14]. In experimental di-
abetes, there is also a decrease in SPARC in the cortexReceived for publication April 7, 1999
that is concurrent with an increase in proliferation ofand in revised form August 8, 1999
Accepted for publication August 23, 1999 the tubular cells [15]. Thus, in certain types of renal
disease, SPARC might act as a cell-cycle inhibitor. 2000 by the International Society of Nephrology
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SPARC has also been associated with increased levels bacteria has previously been described [22]. For the large
of type I collagen and TGF-b1 in renal disease. In the amounts of material required for this study, we con-
Thy1 model of mesangial proliferative nephritis, expres- tracted with Colorado State University to grow 100 L of
sion of type I collagen, SPARC, and TGF-b1 occurs bacterial cultures. The bacterial paste was concentrated
concurrently in the mesangium [10, 16, 17]. Similarly, in by filtration, lysed by high-pressure homogenization in
the passive Heymann nephritis model of membranous the presence of 1 3 1024 mol/L aminoethylbenzene-
nephropathy, the injured podocyte produces increased sulfonylfluoride (AEBSF), and stored in aliquots at
amounts of type I collagen [13, 18], SPARC [13], and 2708C. To maximize our yield of active rSPARC, we
TGF-b [19]. Coexpression of SPARC with type I colla- did not separate soluble proteins from insoluble material
gen [9] and TGF-b1 [20] has also been described in but processed the entire lysate according to the following
the interstitium in experimental models associated with method: A 0.5 L aliquot, corresponding to 20 L of origi-
tubulointerstitial injury. nal culture, was thawed at room temperature. Total bac-
Therefore, circumstantial evidence indicates that terial protein was denatured by the gradual addition of
SPARC might function either as an antiproliferative fac- solid urea to a final concentration of 8 mol/L. NaH2PO4
tor and/or as a protein modulating the production of was added to a final concentration of 0.1 mol/L. Tris-
TGF-b1 and type I collagen in renal disease. To explore HCl was added to 0.05 mol/L. NaCl was added to 0.5
these possibilities, we performed studies in which recom- mol/L, and the pH was adjusted to 8.0 with 1 N NaOH.
binant SPARC (rSPARC) was administered to rats un- A solution of 10% (wt/vol) octylthioglucoside was added
dergoing experimental glomerulonephritis. We report next to produce a final concentration of 0.5%. This mix-
that SPARC had only minimal effects on glomerular cell ture was stirred at room temperature for one to two
proliferation. However, SPARC was found to stimulate hours, and the remaining insoluble material was removed
both the expression of TGF-b1 and the deposition of by sedimentation at 6000 3 g. Because this construct of
type I collagen in vivo, as well as the synthesis of TGF-b1 rSPARC contains a histidine hexamer at its C-terminus,
by mesangial cells in vitro. These observations indicate we isolated rSPARC by nickel-nitriloacetic acid (Ni-
that SPARC might mediate the production of TGF-b1 NTA) metal-chelate affinity chromatography [22, 23].
in renal disease, and they provide a potential mechanism While SPARC was immobilized on the Ni-NTA resin,
whereby matricellular proteins function during the glo- a gradient from 8 to 0 mol/L urea was pumped through
merular response to injury. the column in the presence of a mixture of reduced and
oxidized glutathione. During the early portion of this
METHODS gradient, the solubility of rSPARC is enhanced through
the formation of disulfide bonds between Cys138-Cys248Rat glomerular mesangial cell cultures
and Cys256-Cys272. The final steps in the renaturationThese studies were performed with primary cultures
of rSPARC involve the isomerization of the five disulfideof rat glomerular mesangial cells isolated from kidneys
bonds of the follistatin-like module [22]. After a high-of six male Sprague-Dawley rats weighing 75 to 100 g
resolution gel filtration chromatography step, prepara-[21]. Mesangial cells were grown in RPMI media that
tions of rSPARC were obtained that were .98% freecontained 15% fetal bovine serum (FBS), 15 mmol/L
of contaminating proteins. Yields were 10 to 20 mg ofN-[2-hydroxyethyl]piperazine-N9-[2-ethanesulfonic acid]
active monomeric protein per 20 L of culture. Biophysi-(HEPES), 89 mg/mL sodium pyruvate, 200 mmol/L
cal comparisons of rSPARC with native, murine SPARCl-glutamine, 81 mg/mL penicillin G, 81 mg/mL streptomy-
demonstrated similar Ca21-dependent conformations, ascin sulfate, and 0.66 U/mL insulin. The pH of this media
assessed by circular dichroism and intrinsic fluorescencewas adjusted to 7.3 with 7.5% sodium bicarbonate. Cells
spectroscopies [22, 23]. Biological activity measurementswere passaged every 72 to 96 hours with trypsin. Cells
of the effect of rSPARC on the spreading of rat mesan-maintained in this manner exhibit many features of dif-
gial cells in vitro followed previously established proce-ferentiated glomerular mesangial cells [10]. Cultured
dures [22–24]. Human rSPARC was found to be 92%cells displayed a stellate morphology and contained
identical to the amino acid sequence of rat SPARC.b-smooth muscle actin and Thy1 by immunostaining.
Recombinant SPARC protein preparations containedCultures failed to stain with OX-1 (leukocyte common
,18 ng endotoxin/mg protein as determined by the Lim-antigen) or with an antibody to von Willebrand factor.
ulus amoebocyte assay [23, 25].Epithelial cell contamination was excluded by visual ex-
Radioiodination of Tyr residues of rSPARC was ac-amination.
complished with N-chloro-benzenesulfonamide (Iodo-
Isolation of biologically-active recombinant SPARC Beads, Pierce, Rockford, IL, USA).
from Escherichia coli Human rSPARC cDNA, minus the signal sequence,
was subcloned into the pAc-gp67 baculovirus expressionThe basic procedure for the expression, isolation, and
renaturation of human endothelial cell SPARC from vector (Pharmingen, San Diego, CA, USA) in frame with
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the viral gp67 signal sequence (A. Bradshaw, J. Bassuk, chased from Santa Cruz Biochemicals (Santa Cruz, CA,
USA). Antifibronectin #AB1942 was affinity purifiedJ. Carbon, and E.H. Sage, manuscript in preparation).
Recombinant baculovirus was generated by cotransfec- from rabbit antiserum by Chemicon and was adsorbed
with other rat plasma proteins [27]. Mouse IgG1 thattion of the pAC-gp67/SPARC vector linearized baculo-
virus (AcUW1.lacZ; Pharmingen) into Sf9 cells. Cultured recognized the 90 to 100 kd tissue macrophage ED-1
protein was purchased from Serotec (#MCA341; Ra-supernates were analyzed for rSPARC-Sf9 expression
by immunoblot analysis with four separate SPARC anti- leigh, NC, USA). Goat antitype IV collagen antibody
was purchased from Southern Biotechnology Associatesbodies. Transfected cell supernates were used to generate
high-titer stocks of recombinant virus for future infections. (# 1340-01; Birmingham, AL, USA). Glomerular endo-
thelial cells were identified by their immunoreactivityFor purification, infected supernates in protein-free media,
adjusted to 20 mmol/L 3-[N-morpholino-propanesulfonic with the RECA-1 monoclonal antibody (gift of A.
Duijestijn) [28]. Mesangial cells were identified withacid] (MOPS, pH 6.5), were passed over a Q-Sepha-
rose Fast Flow (Pharmacia, Piscataway, NJ, USA) anion- monoclonal antibodies to the Thy1 antigen (OX-7; Sero-
tec). Proliferating cells were identified by immunostain-exchange column equilibrated in 200 mmol/L LiCl, 20
mmol/L MOPS (pH 6.5). rSPARC-Sf9 was eluted from ing for the proliferating cell nuclear antigen (PCNA;
19A2, Coulter Immunology, Hialeah, FL, USA). To de-the column with a continuous gradient from 200 to 400
mmol/L LiCl in 20 mmol/L MOPS (pH 6.5). The peak tect the His motif of rSPARC, we used mouse mono-
clonal antibodies specific for His (Invitrogen, Carlsbad,fractions were determined by spectrophotometry at OD280
and were confirmed by sodium dodecyl sulfate-polyacryl- CA, USA). Controls for immunohistochemistry included
either the deletion of the primary antibody or the substi-amide gel electrophoresis (SDS-PAGE). rSPARC-Sf9
fractions were pooled, dialyzed against 0.1 N acetic acid, tution of the primary antibody with equivalent concen-
trations of an irrelevant murine monoclonal antibodylyophilized, and solubilized prior to experimental use.
or preimmune rabbit IgG. For each biopsy, 40 to 70
Infusion of rSPARC into animals glomerular cross-sections were evaluated in a blinded
fashion. Scoring of antibody:immunoperoxidase stainingMale Wistar rats (180 to 200 g) received goat anti-
Thy1 plasma (0.4 mL/100 g body weight) intravenously of glomeruli was done semiquantitatively by a previously
published method [13]. Briefly, diffuse, very weak, or noon day 0. On day 2, animals were anesthetized by an
intramuscular injection of ketamine, xylazine, and ace- staining of the glomerular tuft was scored as 0. Increased
staining of 1 to 25% of the tuft was scored as 1. Stainingpromazine (50, 5, and 1 mg/kg, respectively). Polyethyl-
ene tubing (PE-10) was run from an osmotic mini-pump of 26 to 50% of the tuft was scored as 2. Staining of 51
to 75% of the tuft was scored as 3, and staining of .75%(Alzet model 1003D; Alza Corp., Palo Alto, CA, USA)
implanted subcutaneously into the external jugular vein of the tuft was scored as 4. This scoring system has
been shown to be reproducible, and the data obtainedat the back of the neck of each animal. Two pumps were
used per animal, with tubing to each jugular vein. Each correlated significantly with those obtained by computer-
ized morphometry [29, 30].pump contained 100 mL rSPARC at a concentration
of 4.8 mg/mL in Ringer’s lactate solution. The nominal Double immunohistochemical staining was performed
according to the following procedure: The number ofpumping rate was 1 mL/hr, and the duration of pumping
was 72 hours. The delivery rate for rSPARC was 4.8 proliferating glomerular mesangial or endothelial cells
was determined by staining with PCNA, a marker ofmg/h. Control animals (N 5 4) received Ringer’s lactate
solution. After implantation of the pumps, each rat of cell proliferation, and OX-7, a mesangial cell-specific
marker, or RECA-1, an endothelial cell-specific marker,the SPARC group received an intravenous injection into
the tail vein of 500 mg rSPARC. Control animals received as previously described [30]. Briefly, the first mouse
monoclonal antibody (OX-7 or RECA-1) was incubateda 0.1 mL injection of Ringer’s lactate solution. Each
animal of the SPARC group (N 5 4) thus received 1190 16 hours at 48C, followed sequentially by biotinylated
rabbit antimouse IgG (Zymed, San Francisco, CA, USA),mg rSPARC over the course of the experiment.
peroxidase-conjugated Avidin D (Vector, Burlingame,
Immunohistochemical staining CA, USA), and color development with 3,39-diamino-
benzidine (DAB) exclusive of NiCl2. Next, the secondRenal biopsies were fixed in methanol:chloroform:
acetic acid (6:3:1), embedded in paraffin, and sliced into primary antibody (PCNA) was applied for 16 hours at
48C, followed by peroxidase-conjugated rat antimouse4 mm thick sections. Selected sections were stained with
periodic acid-Schiff reagent and counterstained with he- IgM antibody (Zymed) and DAB with NiCl2. Controls
for all double-staining procedures consisted of the omis-matoxylin. Immunoglobulins specific for rat native type
I collagen were produced in guinea pigs and have been sion of either secondary antibody or the omission/replace-
ment of the primary antibody with an irrelevant mousedescribed [26]. Rabbit IgG that recognizes a C-terminal
region in rat TGF-b1 (amino acids 328 to 352) was pur- monoclonal antibody. The number of proliferating glo-
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merular mesangial or endothelial cells was evaluated by ethidium bromide. A photograph was taken, and the
negative was scanned to produce a digitized computercounting the number of cells that stained for both PCNA
(black) and OX-7 (brown) or RECA-1 (brown). Data file. ImageQuante software (Molecular Dynamics) was
used to determine the sum of all pixels in each bandwere expressed as the mean 6 se per glomerular cross-
section. (volume integration) minus the background. Final data
(N 5 3) were expressed as the ratio of the mean pixel
Analysis of transforming growth factor-b1 mRNA volume of each TGF-b1 band (6se) to the mean pixel
in vitro volume of either GAPDH or rpL37. Fold increase of
TGF-b1 mRNA was calculated according to the follow-Total RNA from cultured mesangial cells was isolated
with 1 mL of Tri Reagentt (Molecular Research Center, ing formula:
Cincinnati, OH, USA) per 10 cm2 area of culture dish
(typically a 12-well plate). After dissolution and sedi-
TGF-b1 mRNA @ 45 mg/mL rSPARC
rpL37 mRNA @ 45 mg/mL rSPARCmentation at 10,000 3 g for 10 minutes at 48C, solubilized
material was extracted with 0.2 mL CHCl3 mL21 Tri
4
TGF-b1 mRNA @ 0 mg/mL rSPARC
rpL37 mRNA @ 0 mg/mL rSPARCReagent, vortexed for 15 seconds, incubated at ambient
temperature for 15 minutes, and centrifuged at 12,000 3 g
In some experiments, GAPDH mRNA levels werefor 15 minutes at 48C. The aqueous phase was transferred
substituted for rpL37 mRNA levels.to a fresh tube, and RNA was precipitated with 0.5 mL
2-propanol mL21 Tri Reagent. RNA was recovered by
Analysis of transforming growth factor-b1 proteinsedimentation at 12,000 3 g for eight minutes at 48C.
in vitroBecause cultured mesangial cells typically contain an
Enzyme-linked immunosorbent assays (ELISAs) ofabundance of contaminating polysaccharides at this stage,
total rat TGF-b1 present in rat mesangial cell condi-the RNA pellet was processed further by the addition
tioned media were performed with a kit from Santa Cruzof 0.5 mL 4 mol/L LiCl, vortexing, and incubation at
Biotechnology that contained a monoclonal antibodyambient temperature for one hour. RNA was precipitated
specific for amino acids 328 to 352 of rat TGF-b1 andfrom dissolved polysaccharides with 0.5 mL 2-propanol.
expressed our data (N 5 3) as mean 6 se. For measure-After a brief wash of the RNA pellet with 70% ethanol,
ment of TGF-b1 activity, we used the mink lung epithe-the air-dried RNA was dissolved into nuclease-free water
lial cell (MvLu1) inhibition assay. Briefly, cultures were(pH 8.0). The concentration was determined by the ab-
seeded at 2.5 3 104 per mm2 of a tissue culture plastic wellsorbance at 260 nm. Specific oligonucleotide primers were
and were allowed to attach for one hour. Conditionedgenerated to detect rat TGF-b1 RNA synthesis in mesan-
medium that had been heated to 808C for 10 minutesgial cells. Reverse transcription and the polymerase chain
was added (0.01 to 0.05 mL) to the MvLu1 cells. Afterreaction (RT-PCR) were used to develop a method that
15 hours, 1 mCi/mL [methyl-3H]-thymidine (6.7 Ci/mmol;quantitated the levels of TGF-b1 mRNA relative to un-
New England Nuclear, Boston, MA, USA) was added toregulated RNA species, for example, glyceraldehyde-
the cells, and incubation was continued for an additional3-phosphate dehydrogenase (GAP-DH) and ribosomal
three hours prior to methanol fixation, acid precipitation,protein L37 (rpL37). All oligonucleotide primers were
and liquid scintillation counting of radiolabeled DNA,standardized to the number of thermocyles with respect
as previously described [31]. Data from quadruplicateto the linearity of the Taq polymerized PCR DNA prod-
wells were expressed as mean 6 se.uct. Identical reactions were set up with TGF-b1, GAPDH,
and rpL37 oligonucleotide primers. At the indicated
Statistical analysisnumber of cycles, one tube was removed from the ther-
Analysis of variance was calculated with SYSTAT formocycler and was placed on ice to quench the reaction.
Windows (SYSTAT, Inc., Evanston, IL, USA). ValuesEquivalent volumes of each RT-PCR reaction were re-
are expressed as mean 6 se. Statistical significance wassolved by electrophoresis, and the area of each band was
defined as P , 0.05 and was evaluated by a t-test.determined by densitometric imaging. Linearity of DNA
product was achieved between 24 and 34 cycles. rSPARC
(50 mg/mL), in a solution that also contained 1% FBS RESULTS
and Dulbecco’s modified Eagle’s medium (DMEM), was
Regulation of mesangial cell behavior by rSPARCadded to semiconfluent cells (12-well plates) that were
in vitrorendered quiescent by serum-reduction for 48 hours
We have previously shown that rSPARC is biologi-prior to addition of rSPARC for 16 hours. Parallel con-
cally active in vitro through its inhibition of the PDGF-trol wells received 1% FBS and DMEM. Aliquots of each
dependent proliferation of rat mesangial cells [10]. ThisRT-PCR (30 cycles) were resolved by electrophoresis in
triplicate on agarose gels. DNA bands were stained with observation is consistent with our prior reports that na-
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Fig. 1. SPARC regulates the expression of transforming growth factor-b1 (TGF-b1) mRNA by rat mesangial cells in vitro. (A) Primer standardiza-
tion. Quantitation of RT-PCR DNA product as a function of thermocycles. A series of identical reactions was set up with TGF-b1 (d), GAPDH
(m), and L37 (j) oligonucleotide primers. At the indicated number of cycles, one tube was removed from the thermocycler and placed on ice to
quench the reaction. Equivalent volumes of each RT-PCR reaction were resolved by electrophoresis, and the volume of each band was determined
by densitometric imaging. Linearity of DNA product is between 24 and 34 cycles. (B) RT-PCR analysis of SPARC induction of TGF-b1 mRNA.
rSPARC (50 mg/mL) was added to semiconfluent cells (12-well plates) that were rendered quiescent by reduction of FBS for 48 hours prior to
addition of rSPARC for 16 hours. Parallel control wells did not receive SPARC. Aliquots of each RT-PCR (30 cycles) were resolved by
electrophoresis in triplicate, and the volume of each band was determined by densitometric imaging. Symbols are: (j) GAPDH RT-PCR DNA
product; (h) TGF-b1.
tive, murine SPARC and rSPARC each inhibited the rations of human SPARC expressed in Sf9 insect cells.
rSPARC-Sf9 exhibited a 2.8-fold stimulation of TGF-b1proliferation of endothelial cells [22, 23]. To ascertain
whether rSPARC could inhibit the spreading of rat mes- (relative to L37 mRNA) over untreated, early passage
mesangial cells (data not shown). The lack of glycosyla-angial cells in vitro, we collected photographic images
tion in bacterial rSPARC might account for this differ-at 0, 1, 2.5, and 4 hours after plating cells in the presence
ence.of 1% FBS and 50 mg/mL rSPARC. After their conver-
Because rSPARC appeared to regulate steady-statesion into digitized computer files, we examined fields that
levels of TGF-b1 mRNA in cultured rat mesangial cells,contained .200 cells and categorized them according to
we next asked what effect rSPARC might have on thetheir shape. Over the four hours of scoring, rSPARC
synthesis and secretion of the protein. We measuredwas effective in reducing by 80% the number of spread
total TGF-b1 protein secreted into the medium by mes-cells (data not shown). Our preparations of rSPARC
angial cells with a polyclonal antibody that recognizes awere thus biologically active.
C-terminal region of rat TGF-b1 (amino acids 328 to
rSPARC induces synthesis and secretion of TGF-b1 352; Fig. 2A). Background levels of TGF-b1 secreted
by mesangial cells in vitro into serum-free medium were used as a common denomi-
nator in determining the percentage of control (ordi-Using RT-PCR, we developed a method to quantitate
the levels of TGF-b1 mRNA in cultured rat mesangial nate). In this ELISA-based assay, 15% FBS was found
to increase detectable TGF-b1 protein in the medium bycells relative to an unregulated mRNA, for example,
GAPDH or L37 mRNA. Figure 1A shows our measure- 540%. We also tested the effect of 10 ng/mL recombin-
ant platelet-derived growth factor (PDGF)-B chain onments of DNA product as a function of thermocycles.
The optimal number of thermocycles for TGF-b1, rat mesangial cells and found a 156% increase in
total TGF-b1 protein secreted into the medium. WithGAPDH, or L37 mRNA falls between 28 and 32. This
calibration indicates that the relative quantity of TGF-b1 rSPARC (50 mg/mL, 1.6 mmol/L) added in the absence
or presence of PDGF-B, we observed an increase ofis proportional to the densitometric signal. We found
that cells incubated with rSPARC exhibited 2.3- and 2.9- 308 or 337%, respectively. The difference between these
latter two values is not significant (P 5 0.76) and indi-fold higher steady-state levels of TGF-b1 mRNA (Fig.
1B) relative to untreated cells, whereas levels of cates a lack of synergism between rSPARC and PDGF-B
in the regulation of TGF-b1 protein in these cells.GAPDH mRNA (Fig. 1B) and L37 mRNA (data not
shown) remained constant. We also evaluated our prepa- The Mv1Lu cell inhibition assay was used as a second
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Fig. 2. Induction of secreted TGF-b1 protein
by rSPARC in rat glomerular mesangial cells
in vitro. (A) Total TGF-b1 protein in the con-
ditioned media was measured by ELISA with
a rabbit polyclonal IgG specific for amino acid
residues 328 to 352 of rat TGF-b1. Growth-
arrested cells were treated with control re-
agents (15% FBS; 10 ng/mL of PDGF-B) or
50 mg/mL rSPARC or rSPARC 1 PDGF-B
together. TGF-b1 protein levels were normal-
ized with respect to total protein content.
Shown on the ordinate is the percentage of
control media (DMEM that contained 0.5%
FBS). (B) Heat-inactivated conditioned me-
dium assayed for TGF-b1 activity by the
Mv1Lu epithelial cell [3H]-thymidine incorpo-
ration assay.
method to determine whether TGF-b1 protein is pro- thymidine incorporation by 11.5 (P 5 0.0035) and 14.7%
(P 5 0.0027) at 25 mg/mL of rSPARC and 54.5 (P 5duced by mesangial cells treated with rSPARC. Mv1Lu
cells express all the known TGF-b receptors (types I, 0.0002) and 46.7% (P 5 0.0004) at 50 mg/mL rSPARC.
The specificity of the assay for TGF-b1 was confirmedII, III, and IV) and exhibit both growth inhibition and
transcriptional activation in response to TGF-b [32]. Fig- by our demonstrating that the inhibitory activity of
rSPARC-conditioned mesangial cell media could beure 2B shows the representative results from two of five
such experiments. Background levels of TGF-b1 in the blocked with anti-TGF-b1 antibodies. Furthermore, the
addition of rSPARC directly to Mv1Lu cells did notconditioned medium of cells that did not receive
rSPARC stimulated [3H]-thymidine incorporation by 5.6 inhibit their proliferation (data not shown). The com-
bined data in Figure 2 demonstrate that rSPARC stimu-and 10.8% in two experiments, values that represent the
basal levels of TGF-b1 secreted by these cells in culture. lated rat mesangial cells to synthesize and secrete func-
tional TGF-b1, which was active on Mv1Lu cells as anThe addition of conditioned media from rSPARC-
treated mesangial cells to Mv1Lu cells inhibited [3H]- inhibitor of DNA synthesis.
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Fig. 3. Recombinant SPARC (rSPARC) infused into rats is cleared from the bloodstream and accumulates in the kidneys in an intact form. (A)
Injection of [125I]-rSPARC into tail veins of normal rats. At the indicated times, blood samples were removed. Plasma was prepared, and the
amount of radioactivity determined by gamma counting. Biphasic curve is due to rapid clearance (,15 min) of one half of total input radioactivity,
followed by clearance of remainder over 24 hours. (B) At 24 hours, organs were removed, weighed, minced, and dispersed into scintillation fluid.
(C) From the organs dissected in (B), protein was extracted from tissues, mixed with SDS-sample buffer that contained 0.05 mol/L dithiothreitol
and fractionated by 10% polyacrylamide gels that contained 0.1% SDS. Gels were exposed to x-ray film, which subsequently was processed by
densitometric scanning. Shown is a Rf analysis, in which the asterisk represents the position of the 33 kd rSPARC and two asterisks represent
that of the dye front.
rSPARC injected into normal rats localizes to the into the jugular veins for an additional 72 hours. Five
days after the initial injection, we analyzed tissue speci-kidneys in an intact form
mens from animals that received either Ringer’s solutionAfter injection of 75 mg [125I-rSPARC] (specific activ-
or rSPARC by immunohistochemical staining with aity 5 3.4 3 106 cpm/mg) into the tail veins of normal
monoclonal antibody specific for the C-terminal His tagadult rats (150 g, N 5 3), we collected blood samples and
of rSPARC. Figure 4 demonstrates that exogenousdetermined the amount of radioactivity in total blood or
rSPARC was readily detected within kidney glomeruli.in plasma. Figure 3A displays the amount of radioactivity
Control glomeruli from animals with anti-Thy1 diseaserecovered as a function of time. From 15 minutes to 24
that received Ringer’s-lactate solution did not react withhours, the remaining plasma cpm diminished from 7 to
the anti-His tag antibody (Fig. 4A), whereas the animals,1%, respectively. The biphasic curve was due to rapid
that received rSPARC displayed a strong immunoreac-clearance (, 15min) of one half of the total input radio-
tivity (Fig. 4B). All glomeruli examined (.200) in ani-activity, followed by clearance of the remainder over 24
mals treated with rSPARC reacted with the anti-Hishours. We also recovered the organs from three different
IgG. Because the data in Figure 4 were generated fromanimals and determined the amount of radioactivity g21
animals two days after the infusion of rSPARC, it is
of tissue. Figure 3B demonstrates that all tissues con-
apparent that the protein had undergone a sequestration
tained radiolabeled material and that the kidney was the in glomeruli.
principal organ of accumulation. From each organ, we Previous work from our laboratories demonstrated
extracted protein samples and fractionated them by SDS- that levels of endogenous SPARC and PDGF-B proteins
PAGE. Figure 3C shows densitometric scans of fluores- are maximal at approximately day 5 after an injection
cent autoradiograms. [125I]-rSPARC accumulated in each of anti-Thy1 antiserum into adult rats [9]. In addition,
organ as an intact protein of 33 kd (single asterisk), a the number of proliferating mesangial cells, identified
value in agreement with the known size of rSPARC by immunostaining with both antibodies specific for
synthesized by E. coli [22, 23]. The signal at the dye front smooth-muscle actin and for PCNA, was also found to
(double asterisks) represents radiodecayed material. be maximal at day 5 [9]. We therefore asked whether
the infusion of rSPARC could influence the number of
Administration of rSPARC to rats undergoing PCNA-positive mesangial cells. Table 1 shows data from
anti-Thy1 experimental glomerulonephritis immunohistochemical staining of control rats and of rats
We began the experiment by inducing nephritis with infused with rSPARC at days 3 and 5 after an injection
a single injection of anti-Thy1 antibodies into the tail of the Thy1-antiserum. Although infusion of rSPARC
veins of two groups of four adult rats. After an initial reduced the mean number of proliferating (PCNA1)
injection of 500 mg rSPARC (in 0.1 mL Ringer’s lactate mesangial cells (OX-71) per glomerulus at days 3 and 5
solution) into the tail veins of four adult rats, osmotic (Table 1), these differences were not statistically signifi-
cant.mini pumps, which delivered 4.8 mg/h, were implanted
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Table 2. Influence of rSPARC on the abundance of TGF-b1,Table 1. Influence of rSPARC on the proliferation of mesangial
cells in rats treated with anti-Thy1 antiserum ECM proteins, macrophages, and cycling endothelial cells
in the Thy1 model
Infusion Day 3 Day 5
Antigen rSPARC infusion Ringer’s infusion
Ringer’s-lactate solution 2.0560.80 4.95 61.12
rSPARC 1.6860.28a 4.5060.73b TGF-b1 3.0560.12a 2.3760.07
a1(I) Collagen 2.4760.07a 2.1760.08More than 70 glomeruli from 4 animals of each group were scored by calcula-
Fibronectin 2.9360.1a 2.5460.04tion of the mean number of (PCNA 1 OX-7 positive cells)/glomerulus, 6se.
a1(IV) Collagen 2.5060.11 2.3860.68a P of mean difference 5 0.67; P , 0.05 is considered significant by t-test
ED1 (macrophages) 12.4360.59 11.9261.10b P of mean difference 5 0.75; P , 0.05 is considered significant by t-test
RECA-1b
(cycling endothelial cells) 0.2360.05 0.3760.08
Data are mean score 6 se. More than 70 glomeruli from 4 animals of each
group were scored as follows: 0, diffuse, very weak or no staining of the glomeru-Immunohistochemical quantitation from day 5 biopsy
lar tuft; 1, 1–25% of the tuft; 2, 26–50% of the tuft; 3, 51–75% of the tuft; 4,
specimens is shown in Table 2. Infusion of rSPARC .75% of the tuft. All antigens were measured by immunohistochemistry at day
5 after injection of anti-Thy1 antiserum. Abbreviations are TGF-b1, transformingresulted in increases in immunohistochemical scores for
growth factor-b1; ECM, extracellular matrix; rSPARC, recombinant SPARC.
TGF-b1 (0.68, P 5 0.002), type I collagen (0.30, P 5 a P , 0.05 is considered significant by t-test
b Scored by immunohistochemistry as positive for RECA-1 and PCNA0.027), and fibronectin (0.39, P 5 0.01) compared with
vehicle-injected rats with anti-Thy1 disease. Figure 5
shows representative glomeruli, immunostained for the
indicated antigens, from animals infused with Ringer’s rSPARC was used to demonstrate specific localization
lactate solution and with rSPARC. Periodic-acid Schiff of rSPARC to glomeruli. The glomerular sequestration
reagent (PAS) was used to visualize the overall matrix. of rSPARC (or its extravasation) in animals undergoing
A comparison of Figure 5E with Figure 5A reveals the experimental glomerulonephritis raised several possibili-
matrix expansion in rats infused with rSPARC relative ties regarding the mechanism(s) responsible for the re-
to that of control animals. Immunohistochemical staining tention of the infused protein: (a) rSPARC undergoes
for TGF-b1 (Fig. 5 B, F) and for type I collagen (Fig. 5 specific binding to vitronectin [8], already present in glo-
C, G) is representative of .70 glomeruli scored from meruli at day 2 by its association with the terminal attack
each of four animals per group. No difference in type complex C5b-9 of complement [37]. (b) N-terminal Gln
IV collagen deposition was observed (Table 2). Immuno-
residues, present in the infused protein, are known to
reactivity for type I collagen was more pronounced in
be a substrate for transglutaminase [38], which would
the interstitium of rats infused with rSPARC (data not
cross-link rSPARC to the glomerular matrix. Indeed,
shown), a result consistent with a prior study that linked
binary complexes between SPARC and vitronectin haveinterstitial disease and elevated collagen levels with in-
been shown to be stabilized by tissue transglutaminase-creased SPARC protein in interstitial fibroblasts [9].
mediated cross-linking in vitro [8]. (c) rSPARC could be
endocytosed by glomerular cells, possibly after extrava-
DISCUSSION sation across the endothelial cell barrier, and could inter-
act with mesangial cells. We have noted the uptake ofWe have previously reported that SPARC is expressed
rSPARC by avian cells in culture [39].in various models of renal disease in association with cell
It was our initial hypothesis that rSPARC would re-proliferation, matrix expansion, and TGF-b1 expression.
duce MC proliferation in this model, as it inhibits MCThe function of SPARC in these models has been uncer-
proliferation in response to PDGF in vitro [10]. How-tain, but studies in vitro had indicated a potential role
ever, only a minor and insignificant reduction in bothas an antiproliferative factor [10]. In addition, the consis-
mesangial and endothelial cell proliferation was demon-tent localization of SPARC with type I collagen [9] impli-
strated in the rSPARC-treated rats. An unanticipatedcated SPARC in ECM deposition. For the current study,
finding was increased expression of TGF-b1 and in-we generated rSPARC and showed that it maintained
creased deposition of type I collagen and fibronectin.functional activity by its reduction of adhesion of cul-
Because the biosynthesis of type I collagen and fibronec-tured mesangial cells. After intravenous injection of ra-
tin by mesangial cells is stimulated by TGF-b1 [35], it isdiolabeled rSPARC, a significant amount of rSPARC
likely that increases in these proteins are due, at leastwas found in the kidney, where it was localized as an
in part, to elevated expression of TGF-b1. Studies in vivointact protein.
were consistent with this hypothesis, that is, rSPARCWe subsequently administered rSPARC to rats with
increased TGF-b1 mRNA (by RT-PCR) and TGF-b1mesangial proliferative nephritis (Thy1 model) in which
protein (by ELISA and Mv1Lu assays).there is a limited complement-dependent mesangiolysis
We also used the rSPARC-Sf9 protein to identify po-[33], followed by PDGF-driven mesangial cell prolifera-
tential regions of SPARC that could be responsible fortion [34] and TGF-b1–mediated ECM expansion [35, 36].
An antibody specific for the C-terminal His sequence of the induction of TGF-b1 in vitro. The rSPARC-Sf9 pro-
Fig. 4. Infusion of His-tagged rSPARC into rats undergoing experi-
mental Thy1 glomerulonephritis results in specific localization to glo-
meruli. Paraffin-embedded sections from rats undergoing experimental
Thy1 glomerulonephritis were incubated with mouse IgG specific for
C-terminal (His)6. rSPARC:IgG complexes were visualized with a goat
antimouse IgG antibody followed by a colorimetric reaction. (A) Con-
trol infusion of buffer vehicle into rats for three days. (B) rSPARC
infusion into rats for three days shows localization of rSPARC to glo-
meruli.
Fig. 5. TGF-b1 and type I collagen are induced in glomeruli by the infusion of rSPARC during Thy1 glomerulonephritis. (A–D) Control animals
infused with Ringer’s lactate solution at day 5 post-Thy1 injection. (E–H ) Animals infused with rSPARC in Ringer’s lactate solution at day 5
post-Thy1 injection. Shown are representative photomicrographs from sections stained with periodic acid-Schiff stain, for TGF-b1, for type I
collagen, and for fibronectin (magnification 3400).
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tein, expressed in a baculovirus system and containing residues from the C-terminal, extracellular Ca21-binding
domain to form a region that binds to cells [54], reducescarbohydrate, was not appreciably different relative to
the nonglycosylated bacterial protein. Carbohydrate in their spreading [24], inhibits their proliferation [55], and
disassembles focal adhesions [56]. Ongoing studies willSPARC is of a complex type that spans the linker region
between the central, Cys-rich follistatin-like domain and define the residues of SPARC that regulate the expres-
sion of TGF-b1–mediated matrix expansion that occurthe C-terminal EC-domain [40]. The Cys-rich region
likely interacts with growth factors of the cysteine-knot in renal disease.
family, of which TGF-b1 and PDGF are members, and
is highly similar to a Cys-rich region in follistatin, a pro- ACKNOWLEDGMENTS
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